Background: Central nervous system (CNS) relapse is an uncommon but dramatic complication of diffuse large B-cell lymphoma (DLBCL). Several studies have demonstrated the superiority of cerebrospinal fluid (CSF) flow cytometry (FCM), as compared with conventional cytology (CC), in detecting occult leptomeningeal disease. The clinical relevance of a positive FCM still has to be clarified.
introduction
Central nervous system (CNS) relapse is a relatively rare but devastating complication of diffuse large B-cell lymphoma (DLBCL) [1] [2] [3] . CNS disease might manifest either as meningeal lymphomatosis or in the form of parenchymal or epidural tumors. CNS disease is uncommon at initial diagnosis and most frequently appears either as an isolated relapse or in addition to a systemic relapse. The probability of CNS relapse at 1 year after diagnosis was estimated between 3% and 5% in the pre-rituximab era [1] [2] [3] [4] . Whether the addition of rituximab to chemotherapy lowers the risk of CNS relapse is a matter of debate [5] [6] [7] [8] .
Considering the low incidence of this disease manifestation, CNS prophylaxis is not felt to be systematically warranted for DLBCL patients, in contrast to what is recommended in the treatment of diseases with a very high risk of CNS relapse, such as acute lymphoblastic leukemia or Burkitt's lymphoma.
Several large-scale retrospective studies have identified easily accessible risk factors associated with an increased risk of CNS recurrence. Advanced-stage disease, elevated lactate dehydrogenase (LDH), extranodal involvement, notably number of extranodal sites and specific disease locations (testis, breast, Waldeyer's ring, bone marrow, .), all are recognized risk factors for this outcome [1, 2] . A multivariate logistic regression analysis showed that increased LDH and more than one extranodal site of disease (ENS) were independent predictors of CNS disease and, together, conferred a probability of CNS recurrence at 1 year of 17% [1] . As CNS-directed prophylaxis is associated with increased toxicity and discomfort to patients, the identification of more reliable predictors of CNS disease would be of particular interest.
CNS relapse most frequently occurs early in the disease course [1, 2] , and this fact could be explained by the presence of 'occult' CNS disease at diagnosis. Standard light microscopic evaluation of cerebrospinal fluid (CSF) samples has shown to be insufficient to diagnose leptomeningeal disease in a considerable number of patients. Several studies have shown a superior sensitivity of flow cytometry (FCM) in detecting leptomeningeal disease, when compared with conventional cytomorphology [9] [10] [11] [12] [13] . However, all published studies combined patients with heterogeneous histological diagnoses, and the clinical significance of a positive sample within a given histology remains unclear [14, 15] . The primary goal of our study was to investigate whether a positive FCM result was correlated with an increase in the CNS relapse rate, in an unselected population of DLBCL patients.
patients and methods patients
From September 2005 to May 2009, we analyzed 114 CSF samples from 111 consecutive patients with a diagnosis of DLBCL treated in a single hematology department. Ninety-five patients were assessed at first diagnosis of DLBCL. No specific criteria were used to select patients to be submitted to lumbar puncture, except that it was usually not carried out in very frail and/or elderly patients and in patients without any adverse prognostic factors on the basis of the age-adjusted International Prognostic Index (aaIPI = 0) [16] . Thus, 93 of 154 (60%) patients with newly diagnosed DLBCL presenting to our department during the study period were subjected to analysis. The other 19 samples were analyzed at relapse, 3 patients having been studied both at initial diagnosis and at relapse.
All patients underwent standard staging procedures including cervico-thoraco-abdomino-pelvic computed tomography (CT) scan and bone marrow biopsy. Patients were only submitted to CNS imaging [CT and/or magnetic resonance imaging (MRI)] if neurological symptoms were present. CSF samples were collected by lumbar puncture, before any kind of therapy, and were evaluated for glucose, total protein content, conventional cytology (CC) and FCM.
cytology analysis
All samples were analyzed by standard light microscopy morphology. The number of cells was evaluated, and identification of visible cells was made. Morphologic examination was carried out on cytospin preparations stained with May-Grünwald-Giemsa. The number of cells was evaluated semiquantitatively (0-20 cells per cytospin preparation versus >20). When present, lymphocytes were described as being of normal or atypical morphology and marked for CD19 if there was a suspicion of infiltration.
FCM analysis
For CSF analysis by FCM, we followed the recommendations of our workgroup [17] consisting on the following: CSF samples were processed as soon as possible following lumbar puncture (always within 3 h) and were usually collected directly into a tube containing 400 ll of stabilizing reagent TransfixÒ (Cytomark, Buckingham, UK). The samples were washed in saline buffer (phosphate-buffered saline), counted in trypan blue (to evaluate cellularity and viability), and one-third was labeled with the following antibodies: 1-CD45-FITC, CD3/CD14-ECD, CD19-PC7, CD5-PC5 and CD10-PE.
According to cellularity and clinical data, either the two-thirds of the remaining cells were labeled with the same antibodies (in case paucicellularity had precluded interpretation of the first labeling), or the remaining amount was labeled with complementary antibody combinations: 2-CD20-ECD, CD22-PC5, CD19-PC7, CD45-FITC and 3-Kappa-FITC(Dako)/Lambda-PE(Dako)/CD19-PC5/CD45-(five colors).
All antibodies were purchased from Beckman Coulter, except specified otherwise. Cells were directly stained for 30 min at 4°C and then washed again once. FCM was carried out with a Coulter FC500 within 24 h from the staining. Listmode parameters were analyzed and stored on the software CXPä (Beckman Coulter). Lymphocytes were identified by CD45 expression, forward-scatter (FSC) and side-scatter (SSC) patterns. Positive results were given when a monoclonal population was identified, by surface light chain restriction, or due to an abnormal phenotype of B cells (altered FSC and/or SSC or aberrant antigen expression). Samples were considered positive if they had >5% of CD19+ cells, with phenotypical characteristics similar to the immunohistochemistry found at the time anatomopathological diagnosis was made.
statistical analysis
Patients' characteristics were compared using Fischer's exact test. Differences between the results of comparative tests were considered statistically significant at a two-sided P < 0.05. All statistical analyses were carried out using Statistical Application System software (version 9; SAS Institute, Cary, NC).
results patients
Ninety-five patients were assessed at initial diagnosis of DLBCL. Among these 95, 19 had had an associated low-grade component at diagnosis (transformed follicular lymphoma, n = 11; transformed marginal zone lymphoma, n = 6; transformed nodular lymphocyte-predominant Hodgkin lymphoma, n = 2), 3 of whom had already been treated for a lowgrade lymphoma. According to the 2008 World Health Organization classification, there were seven cases of primary mediastinal (thymic) large B-cell lymphoma; three cases of B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma and one case of monomorphic B-cell posttransplant lymphoproliferative disorder. All other cases were classified as DLBCL, not otherwise specified. Eighty-three cases could be classified according to the immunohistochemical Hans algorithm [18] : 32 had a germinal center phenotype; 51 a non-germinal center phenotype.
Sixty-one percent of patients were males (n = 58), and the median age at diagnosis was 59 years (range: 18-84 years). According to the International Prognostic Index (IPI), 22 patients were low risk, 21 low-intermediate risk, 31 intermediate-high risk and 21 high risk. Six patients had clinical and/or radiological evidence of CNS involvement at diagnosis: focal neurological deficit (n = 2), cranial nerve or radicular palsies (n = 2) and epidural disease (n = 2). Among the remaining patients with no evidence of CNS involvement at diagnosis, 59% had an elevated LDH level, and 44% presented with more than one ENS. Twenty-nine (32%) had both risk factors. There were two cases with primary involvement of the breast, four with predominant involvement of the ear-nose-throat area and one with testicular lymphoma (the latter also having evidence of neurological involvement).
Treatment was decided according to local treatment policies during the study period, age and the number of IPI risk factors. Thirty-five patients were treated in the setting of a clinical trial (mainly promoted by the Groupe d'Etude des Lymphomes de l'Adulte group): first-line treatments included the Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (n = 81) and Rituximab, Doxorubicin, Cyclophosphamide, Vindesine, Bleomycin, Prednisone (R-ACVBP) (n = 9) [19, 20] regimens. Two patients received no treatment because of poor performance status (n = 1) or patient refusal (n = 1), and one patient received an LyMphome de Burkitt de l'Adulte protocolinspired Burkitt-like regimen [21] .
Patients considered at risk for CNS disease based on classical risk factors (including all patients with an aaIPI ‡ 2), who had no neurological symptoms nor evidence of CSF infiltration by Relapsing patients (n = 19) were treated with heterogeneous salvage regimens, according to the clinical setting. Seventeen among the 19 relapsed patients received a rituximab-containing regimen. Chemotherapy regimens included Rituximab, Ifosfamide, Carboplatin, Etoposide (n = 4) [22] and Rituximab, Gemcitabine, Oxaliplatin (n = 6) [23] . According to the clinician's decision, eight patients received intrathecal prophylaxis with MTX (15 mg) + hydrocortisone succinate (50 mg) on day 1 of the first three or four cycles of chemotherapy, and five received triple intrathecal treatment. Thirteen patients had neurological signs or symptoms suggesting CNS involvement at diagnosis or at relapse (Table 1) : three patients had intraparenchymal brain tumors, four had radicular deficits, one had an epidural tumor and five had symptoms suggesting involvement of the cranial basis (e.g. numb chin syndrome). Among these patients, only two were positive by FCM (one CC+), all among the group with cranial basis symptoms.
For the evaluation of clinical outcome, and in order to avoid overestimation of CNS relapse, we excluded patients with symptoms or signs suggestive of CNS involvement. After excluding patients with neurological signs, we had 101 samples eligible for analysis, with 12 having positive FCM results. The clinical and biological characteristics of this population are summarized in Tables 2 and 3 .
Newly diagnosed patients without neurological symptoms (n = 89) were as follows: 54 male and 35 female, with a mean age of 58 years (ranging from 18 to 82 years). The IPI was low (zero to one factor) in 21 patients (23%), low-intermediate (two factors) in 21(23%), intermediate-high (three factors) in 30 (33%), and high (four to five factors) in 17 (19%). Fiftythree patients (59%) had elevated LDH levels, 40 (44%) had more than one ENS, advanced stage was seen in 73 patients (82%) and bone marrow involvement in 37 (41%).
Relapsed patients without neurological symptoms (n = 12) had a median age of 62 years. Elevated LDH levels were seen in six patients (50%), more than one ENS in six (50%), advanced stage in nine (75%) and bone marrow involvement in two (16%).
CNS recurrence and risk factors
The median time of follow-up was 14.2 months. Four patients of 101 (4%) relapsed in the CNS. CNS relapse was leptomeningeal in two patients and parenchymal in the other two. Median time to relapse was 5.2 months (range 1.3-7.8 months).
Within the patients who relapsed in the CNS, only one had an FCM+ CSF before relapse. This patient had a relatively low number of B cells on CMF (i.e. 33).
The outcome of CMF+ patients did not significantly differ from the remaining patients in terms of event-free or overall survival.
The following factors were tested for an association with the risk of CNS relapse: stage, performance status, LDH level, number of extranodal sites, age and number of IPI risk factors. Those factors that have shown an association with CNS recurrence were more than one extranodal site (P = 0.04) and more than one ENS with elevated LDH (P = 0.018)
discussion
In accordance with previous reports, we confirmed the better sensitivity of FCM versus cytology in detecting abnormal cells in the CSF of patients with DLBCL. In our analysis, FCM yielded 14 of 114 positive results, whereas cytology showed only one positive sample, the latter being positive by both techniques. This is in accordance with several studies that have demonstrated that CMF has a superior sensitivity in detecting CNS involvement than CC [9] [10] [11] [12] [13] . However, most of these studies did only provide limited information about patient outcome according to CNS results. Sancho et al. [14] recently reported patient outcomes in a multicentric series of 105 patients (outcomes known for 85% of them) with aggressive lymphomas (67 patients with DLBCL). Although a positive CMF was associated with an increased risk of CNS relapse in this study, CC+ patients (which can be considered as having CNS disease at diagnosis) were mixed with CMF+CC2 patients. Among four CNS relapses observed in this study in CC2 patients, only two were CMF+.
In our study, among patients with symptoms suggestive of CNS involvement, only 2 of 13 had a positive CMF. This underlines the anatomic separation between different compartments of the CNS, e.g. between the brain parenchyma and the meningeal compartment. All 11 CMF2 patients had indubitable CNS involvement on the basis of MRI studies.
Among asymptomatic patients, the high incidence of FCM+ results suggests the existence of occult CNS disease at diagnosis. This hypothesis is also sustained by a low median time to relapse (5.2 months), which is in agreement with the literature stating that CNS relapse appears in the first year after diagnosis. Within our FCM+ patients, only a minority finally relapsed (1 of 12 FCM+ patients). On the other hand, the observation of CNS relapses in patients with negative CSF samples somewhat challenges the presence of occult CNS involvement. We might speculate that CNS involvement appears later in the disease course, in the context of systemic relapse of the lymphoma.
In agreement with the work of van Besien et al. [1] , risk factors that have shown an association with CNS relapse were the presence of more than one ENS and the presence of both original articles Annals of Oncology elevated LDH and ENS >1 (P = 0.04 and P = 0.018, respectively). Certain intrinsic biological characteristics of the tumor have been related to an increased risk of CNS relapse: the presence of a rearrangement of the c-myc locus has been associated with an increased risk of CNS relapse [24] . Interestingly, two of our four cases of CNS relapses had a c-myc rearrangement detectable by FISH (one case being associated with a Bcl2 rearrangement). Unfortunately, all our cases could not be studied by FISH in order to evaluate the proportion of patients with a c-myc rearrangement. Lymphomas that are positive for CD5 by immunohistochemistry also seem to be associated with an increased risk of CNS relapse [25] . Recently, the detection of specific micro RNAs in the CSF of patients with primary CNS lymphoma has been demonstrated to be an interesting diagnostic tool in terms of sensitivity and specificity. This technique should probably be studied in the same setting as our study [26] .
To conclude, although being a more sensitive technique than cytology, FCM evaluation of CSF samples has failed to be predictive of CNS relapse in asymptomatic patients with DLBCL. These results deserve further validation in future prospective trials, which should include populations with a high risk of developing CNS relapse on clinical grounds. Meanwhile, maintaining the use of meningeal prophylaxis in high-risk patients with DLBCL seems reasonable and possibly effective in preventing CNS relapse. CC, conventional cytology; yo, year old; DLBCL, diffuse large B-cell lymphoma; Neg, negative; Pos, positive; A&W, alive and well; CNS, central nervous system; MRI, magnetic resonance imaging; AWD, alive with disease; DOD, died of disease; CT, computed tomography; PTLD, post transplant lymphoproliferative disorder; B-CLL, B-chronic lymphocytic leukemia. 
